Literature DB >> 6206978

Hemodynamic effects of iloprost, a prostacyclin analog.

S Kaukinen, P Ylitalo, T Pessi, H Vapaatalo.   

Abstract

Iloprost is a chemically stable derivative of carbaprostacyclin. We studied its hemodynamic effects in 10 patients in an intensive care unit. Iloprost was infused intravenously for 3 days for the treatment of advanced obliterative arterial disease of the lower extremities. Clinically significant hemodynamic responses were obtained with an infusion rate of 0.5 ng/kg/min. All subjects tolerated the dose of 4 ng/kg/min, which increased heart rate an average of 11% and cardiac index an average of 26%. This infusion rate decreased mean arterial pressure by 15%, total peripheral resistance by 31%, and pulmonary vascular resistance by 34%. Mean pulmonary arterial pressure, pulmonary capillary wedge pressure, left and right ventricular stroke work indices, and rate pressure product did not change. At higher doses of up to 8 ng/kg/min, responses were augmented only slightly, but side effects such as headache, nausea, and abdominal colics became more prominent. The data show iloprost to be a potent vasodilator that reduces both pre- and afterload and presumably induces a compensatory increase in cardiac output and heart rate, but does not increase the work load or oxygen demand of the heart.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206978     DOI: 10.1038/clpt.1984.205

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Pharmacological approaches to the treatment of intermittent claudication.

Authors:  E G Bevan; P C Waller; L E Ramsay
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

2.  Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation.

Authors:  L Caspary; A Creutzig; K Alexander
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. A placebo-controlled dose-response study.

Authors:  H Darius; V Hossmann; K Schrör
Journal:  Klin Wochenschr       Date:  1986-06-16

4.  Clinical effects of intravenous iloprost in patients with intermittent claudication.

Authors:  U Müller-Bühl; C Diehm; T Krais; R Zimmermann; H Mörl; H H Eckstein
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.

Authors:  T W Higenbottam; A Y Butt; A T Dinh-Xaun; M Takao; G Cremona; S Akamine
Journal:  Heart       Date:  1998-02       Impact factor: 5.994

Review 6.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

7.  Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies.

Authors:  Marybeth Sechler; Amber D Cizmic; Sreedevi Avasarala; Michelle Van Scoyk; Christine Brzezinski; Nicole Kelley; Rama Kamesh Bikkavilli; Robert A Winn
Journal:  Pharmgenomics Pers Med       Date:  2013-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.